| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 20.519 | 0 | 25.305 | 23.333 | 30.537 | 34.179 |
| Total Income - EUR | - | - | - | - | 24.489 | 0 | 25.305 | 23.333 | 30.537 | 34.180 |
| Total Expenses - EUR | - | - | - | - | 28.705 | 0 | 34.442 | 34.548 | 38.606 | 46.681 |
| Gross Profit/Loss - EUR | - | - | - | - | -4.217 | 0 | -9.136 | -11.215 | -8.069 | -12.501 |
| Net Profit/Loss - EUR | - | - | - | - | -4.422 | 0 | -9.355 | -11.449 | -8.375 | -12.843 |
| Employees | - | - | - | - | 3 | 0 | 4 | 4 | 3 | 4 |
Check the financial reports for the company - David Alexdio Pavamed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 719 | 0 | 988 | 788 | 267 | 1.265 |
| Current Assets | - | - | - | - | 4.329 | 0 | 1.812 | 843 | 9.329 | 1.994 |
| Inventories | - | - | - | - | 38 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 948 | 0 | 414 | 377 | 224 | 223 |
| Cash | - | - | - | - | 3.343 | 0 | 1.398 | 466 | 9.105 | 1.771 |
| Shareholders Funds | - | - | - | - | -4.379 | 0 | -18.871 | -30.378 | -38.660 | -51.287 |
| Social Capital | - | - | - | - | 42 | 0 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 9.427 | 0 | 21.671 | 32.009 | 48.256 | 54.546 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4333 - 4333" | |||||||||
| CAEN Financial Year |
4333
|
|||||||||
Comments - David Alexdio Pavamed S.r.l.